Drugs / Cantrixil
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02903771 | Dec 2016 → Mar 2020 | fallopian tube cancer, ovarian cancer, peritoneum cancer | Kazia Therapeutics Limited | Completed | Met primary |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2021-06-30 | Oasmia Pharmaceutical AB | Results Cantrixil positive Phase I trial data published in the journal Cancers vivesto.com ↗
Oasmia Pharmaceutical AB, an innovation-focused specialty pharmaceutical company, today announces that the results from a Phase I open-label study (NCT02903771) of the investigational drug candidate Cantrixil (TRX-E-002-1) have been published in Cancers, a peer-reviewed, open access journal of oncology. |
| 2021-04-12 | Oasmia Pharmaceutical AB | Results Oasmia Presents Cantrixil Final Phase I Data at the 2021 AACR Annual Meeting vivesto.com ↗
Oasmia Pharmaceutical AB, an innovation-focused specialty pharmaceutical company, last night presented final data from the dose-escalation and dose-expansion cohorts of a Phase I trial of the investigational drug candidate Cantrixil (TRX-E-002-1) at the American Association of Cancer Research (AACR) annual meeting. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-06-30 | Oasmia Pharmaceutical AB | Cantrixil positive Phase I trial data published in the journal Cancers vivesto.com ↗ |
| 2021-04-12 | Oasmia Pharmaceutical AB | Oasmia Presents Cantrixil Final Phase I Data at the 2021 AACR Annual Meeting vivesto.com ↗ |
| 2021-03-26 | Oasmia Pharmaceutical AB | Oasmia to Present Cantrixil Final Phase I Data at the 2021 AACR Virtual Annual Meeting vivesto.com ↗ |
| 2021-03-01 | Oasmia Pharmaceutical AB | Oasmia acquires global development and commercialization rights for Cantrixil, a clinical stage, ovarian cancer program vivesto.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cantrixil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02903771 ↗ |
| Modality | Small molecule | “a novel third-generation benzopyran molecule” PMID 34206826 ↗ Jun 2021 |
| Route | Other | “Cantrixil will be administered via the intraperitoneal route only.” NCT02903771 ↗ |